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The electrophysiologic properties of flecainide, a new 
potent antiarrhythmic drug, are poorly defined. In this 
study, they were investigated by standard microelec-
trode technique in isolated cardiac muscle from rabbit 
and dog hearts. The concentrations of flecainide used 
were between 0.1 and 10.0 ILg/mI. Flecainide produced 
a concentration-dependent decrease in maximal rate of 
rise of phase 0 of the action potential (V max), action 
potential amplitude and overshoot potential with an in-
crease in the effective refractory period in ventricular 
muscle. V max was reduced by 52.5% after 1 ILg/ml of 
flecainide (p < 0.001) and by 79.8% after 10.0 ILg/ml 
(p < 0.001). The corresponding values for Purkinje fi-
bers were 18.6% (p < 0.01) and 70.8% (p < 0.001), 
respectively, but in these fibers the effective refractory 
period was shortened at the lower concentration and 
restored to control value at the higher concentration. 
Flecainide (R-818). a relatively new investigational antiar-
rhythmic compound. has recently been shown to be effective 
in controlling a number of experimental tachyarrhythmias 
including those induced by aconitine. ouabain. chloroform-
epinephrine and coronary artery occlusion (1.2). Particularly 
noteworthy is the observation that on an mg/kg basis the 
drug has been reported to be 7 to 12 times more potent than 
quinidine, procainamide and lidocaine in suppressing chlo-
roforrn-epinephrine-induced ventricular arrhythmias in mice 
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The depression of V max by flecainide was frequency-de-
pendent. The action potential duration was lengthened 
by flecainide in ventricular muscle and shortened in Pur-
kinje fibers. At high concentrations (10 ILg/ml), flecain-
ide depressed slow channel-dependent fibers. Purkinje 
fiber automaticity induced by isoproterenol was slowed 
by flecainide. 
The data indicate that the overall electrophysiologic 
effects of flecainide in isolated cardiac muscle are com-
plex with a major depressant action on V max that may 
account for its dominant antiarrhythmic effects. It is also 
possible that the differential effects of the compound on 
the action potential duration and refractoriness in ven-
tricular muscle and Purkinje fibers contribute to the 
known arrhythmogenic potential of the drug. 
(J Am Coll CardioI1985;5:303-1O) 
(\). In the intact canine heart, Hodess et at. (3) found that 
ftecainide decreased the ventricular premature beats as a 
function of plasma drug concentration. 
As in the experimental setting. preliminary clinical stud-
ies (4-9) not only have confirmed the extreme potency of 
ftecainide in suppressing premature ventricular contractions 
but also have indicated that the drug has pharmacokinetic 
characteristics appropriate for both short-term intravenous 
as well as long-term oral prophylactic therapy. However. 
little is known about the electrophysiologic basis for the 
observed salutary effects of the compound in cardiac muscle 
(10), and there is no information regarding why. in some 
patients. the compound tends to aggravate ventricular tachy-
arrhythmias (II). Our study was undertaken to define the 
electrophysiologic actions of varying concentrations of fte-
cainide in isolated preparations from dogs and rabbits under 
different experimental conditions. 
Methods 
Animals. Mongrel dogs of either sex (weighing 15 to 
25 kg) were anesthetized with sodium pentobarbital (30 
mg/kg intravenously) and the hearts were rapidly removed 
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and dissected in cool oxygenated Tyrode solution. Prepa-
rations of papillary muscles with attached false tendons com-
posed of Purkinje fibers were obtained from the right ven-
tricle. The preparation was then immersed in a tissue bath 
of 10 ml volume and superfused with Tyrode solution at a 
flow rate of 15 mllmin at 36.0 ± OSc. The composition 
of the Tyrode solution was as follows (mM): sodium chloride 
130, potassium chloride 4.0, calcium chloride 1.8, mag-
nesium sulfate 0.5, sodium phosphate 1.8, sodium bicar-
bonate 18 and dextrose 5.5. The solution was bubbled with 
95% oxygen and 5% carbon dioxide and its pH was main-
tained at 7.24 ± 0.02. 
Superfusion medium and recording of transmem-
brane potentials. Preparations of Purkinje and ventricular 
muscle fibers were stimulated extracellularly through bipolar 
extracellular electrodes. Rectangular pulses, 2 ms in dura-
tion and twice threshold voltage, were applied by a Grass 
S88 stimulator with an isolated output. The stimulus fre-
quency was I Hz, but in some preparations it was increased 
sequentially to 2,3,4 and 5 Hz to determine the influence 
of stimulus frequency. The preparations were equilibrated 
for 90 minutes before the measurements were performed. 
Action potentials were recorded through glass microelec-
trodes filled with 3M potassium chloride having tip resist-
ance of 10 to 30 Mohm. The maximal rate of rise of phase 
o of the action potential (Vma,) was obtained by electronic 
differentiation. Action potentials and their differentiated waves 
were displayed on a Tektronix oscilloscope (type R 564B) 
and photographed on Polaroid film. 
The following variables of action potentials were mea-
sured: action potential amplitude, overshoot, maximal rate 
of rise of phase 0 (V rna,), resting potential and action po-
tential duration at 50% repolarization (APDso) and at 90% 
repolarization (APD9o). The refractory period was deter-
mined by premature stimulation, with premature stimuli (S2) 
of varying coupling intervals being delivered after the 10th 
basic stimulus (S I) at I Hz. The action potentials from a 
fiber were recorded at a distance of 2 to 3 mm from the 
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stimulating electrode. The shortest S I S2 interval that evoked 
an action potential was defined as the effective refractory 
period. 
Production of slow channel-dependent potentials. 
Slow response potentials (12) were produced in isolated 
ventricular muscle preparations stimulated at I Hz when 
superfused with Tyrode solution containing 20 mM potas-
sium chloride and isoproterenol 2 x 1O- 6M. The possibility 
of these potentials being attenuated fast-response potentials 
was excluded by the addition of tetrodotoxin (0.2 j.Lg/ml). 
which had no effect. To determine the cycle length de-
pendency of the action potential characteristics, Purkinje 
fibers were stimulated at various drive cycle lengths. The 
effect of isoproterenol, 2 x 10 hM, on spontaneous dis-
charge in Purkinje fibers was also tested before and after 
0.1, 1.0 and 5.0 j.Lg/ml of flecainide. By this method a 
detectable increase in rate and magnitude of diastolic de-
polarization usually developed after isoproterenol. After the 
effects of isoproterenol were determined and recorded in 
control perfusate, flecainide was administered for 10 min-
utes or longer before a second application of isoproterenol 
was made in the presence of the drug. Ascorbic acid was 
added to the superfusate to retard the degradation of 
isoproterenol. 
Method of drug superfusion. For all experiments, a 
stock solution of flecainide was prepared fresh each day by 
dissolving crystalline flecainide acetate (3M Co., Riker Lab-
oratories) in distilled water to make the final concentration 
from 0.1 to 10.0 j.Lg/ml in Tyrode solution. Multiple con-
centrations of flecainide were administered by the method 
of cumulative addition. Usually, the effects of the drug were 
examined after 30 minutes of superfusion at each concen-
tration of the drug. 
Statistical analysis. The data were analyzed statistically 
by using Student's t test, with the data being expressed as 
mean ± standard deviation. The values were based on the 
individual averages of the data from each preparation (that 
is, multiple impalements). 
Table 1. Effects of Flecainide on the Action Potential Variables of Canine Purkinje Fibers 
APA OS RP Ymax APD50 APDoo 
(mV) (mV) (mV) (Vis) (ms) (ms) 
Control 122.1 ± 1.4 30.8 ± 1.0 91.3 ± 1.8 599.6 ± 19.5 273.5 ± 24.0 338.7 ± 23.5 
F1ecainide, 120.9 ± 1.0 NS 30.0 ± 1.4 NS 90.9 ± 1.8 NS 564.5 ± 29.3 NS 238.2 ± 29.4 NS 307.8 ± 22.6 NS 
0.1 /tg/ml 
Flecainide, 113.5 ± 4.9 t 25.1 ± 2.5* 89.5 ± 3.7 NS 488.3 ± 29.3* 143.1 ± 21.1+ 251.5 ± 28.4:j: 
1.0/tg/ml 
F1ecainide, 90.2 ± 10.7* 5.8 ± 3.6:j: 85.4 ± 3.9 NS 281.3 ± 11.5:1: 79.9:t 17.7:j: 211.8 ± 23.5:j: 
1O.0/tg/ml 
*p < 0.01, tp < 0.05, :J:p < 0.001. APA = action potential amplitude; APDso = action potential duration at 50% repolarization; APD<J() = action 
potential duration at 90% repolarization; NS = not significant; OS = overshoot; RP = resting potential; V rna' = maximal rate of depolarization. The 
data were acquired from six Purkinje fibers with at least six impalements from each preparation and drug concentration which was increased by the 
method of cumulative addition. At control and at each drug concentration, the mean number of impalements was 33 (range 30 to 44). 
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Table 2. Effects of Flecainide on the Action Potential Variables of Canine Ventricular Muscle Fiber 
APA OS RP V max APD,o APD90 
(mY) (mY) (mY) (Y/s) (ms) (ms) 
Control 106.6 ± 1.4 18.5 ± 3.5 li8.2 ± 2.5 290.0 ± 35.2 166.7 ± 8.8 212.3 ± 10.3 
Flecainide, 101.4 ± 3.5 15.2 ± 3.9 86.4 ± 2.5 233.4 ± 44.5 176.5 ± 26.0 233.0 ± 24.0 
0.1 JLg/ml 
Flecainide, 98.8 ± 4.7t 12.8 ± 5.3* li6.0 ± 2.2 137.7 ± 23.4+ 196.1 ± 20.4* 239.2 ± 18.9* 
1.0 JLg/ml 
Flecainide, 89.7 ± 9.4* 6.4 ± 3.6+ 83.3 :t 3.3 61.5 ± 26.4+ 213.7 ± 29.4* 262.3 ± 29.9* 
10.0 JLg/ml 
Abbreviations are the same as those for Purkinje fibers (Table I). The data were obtained from five ventricular muscle preparations with at least six 
impalements from each preparation. In all instances, at each drug concentration and control, at least 30 impalements (range 30 to 42) were obtained for 
the purposes of data analysis to minimize the variability of response due to differences in the variables from different cells. The concentration-dependent 
effects of flecainide were evaluated by the method of cumulative drug addition. 
Results 
Effects on transmembrane resting and action poten-
tials. The mean data demonstrating the effects of varying 
concentrations of ftecainide on canine Purkinje fibers (n = 
6) and ventricular muscle (n = 5) are summarized in Tables 
I and 2. In the range of concentrations used, in neither 
tissue was the resting membrane potential altered signifl-
cantly. There was a differential effect of ftecainidc on rc-
polarization. In Purkinje fibers a concentration-related short-
ening of the action potential occurred at both 50% (APD,() 
and at 90% (APD9() repolarization times, whereas an in-
crease (albeit less striking) was found at APDso and APD90 
in ventricular muscle fibers. In atrial muscle (n = 8) the 
changes were similar to those in ventricular muscle. A con-
centration of O. I /Lg/ml of ftecainide had no significant effect 
on either APD90 or V max' However, I /Lg/ml of the drug 
reduced Vmax by 18.3% (p < 0.01) and lengthened APD90 
by 12.8% (p < 0.05); \0 /Lg/ml of the drug decreased Vmax 
by 26.7% (p < 0.001) with an increase of APD90 by 16.6% 
(p < 0.01). 
The most striking and consistent effect ortfecainide was 
on the upstroke velocity of phase 0 (Vow.) in Purkinjcfihcrs 
and in ventricular muscle (Tables I and 2). The thrcshold 
concentration for the reduction in Vlllax was 0.1 /Lg/ml, but 
significant decreases occurred at ftecainide concentrations 
greater than I/Lg/ml. In Purkinje fibers there was an 18.6'1c 
(p < 0.0 I) reduction after superfusion with a I /Lg/ml con-
centration and a 53. I % reduction after a 10 /Lg/ml concen-
tration (p < 0.00 I). The corresponding figures for ventric-
ular muscle were more pronounced: 52.5% (p < 0.001) and 
79.8% (p < 0.001) reduction, respectively. In both tissues, 
the reduction in V max was accompanied by decreases in the 
action potential amplitude and in overshoot potential. 
Changes in membrane responsiveness and effective 
refractory period. The effect of ftecainide on the relation 
between Vonax and membrane potential ("membrane re-
sponsiveness") in Purkinje fibers was determined by the 
use of premature excitations at different coupling intervals 
during phase 3 of the action potential elicited at a constant 
driven frequency of I Hz. This was tested under control 
conditions and after superfusion successively with 1.0, 2.0 
and 5.0 /Lg/ml concentrations. Flecainide consistently shifted 
the membrane responsiveness curve in the hyperpolarizing 
direction as a function of drug concentration (Fig. I). At 
2.0 and 5.0 /Lg/ml, ftecainide abolished the premature re-
sponses elicited from reduced membrane potentials asso-
ciated with low Vlllax ' For example, under control conditions 
the earliest response could be evoked from a membrane 
potential of - 63 mV with a V""" of 20 Vis. After super-
fusion with I /Lg/ml of ftecainide there was a minimal effect, 
but at higher concentrations of the drug a response was 
clicited only at higher membrane potential. At 2 /Lg/ml 
Figure 1. Changes in the membrane responsiveness curve in a 
Purkinje fiber after varying concentrations of flecainide. Ordi-
nate = dV/dtmax (V max) in Vis; abscissa = level of membrane 
potential (mV); closed circles = control: open squares = after 
I Itg/ml flecainide: closed triangles = after 2.0 Itg/ml flecainide: 
open circles = after 5 Itg/ml of flecainide. The drug shifted the 
membrane responsiveness curve in the hyperpolarizing direction 
in a manner characteristic of a fast channel inhibitor. 
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Figure 2. Effects of flecainide on the effective refractory period 
(ERP) of canine Purkinje fibers and ventricular muscle fibers rel-
ative to alterations in the AOP)o and AOP4o . The changes dem-
onstrated are percent differences from respective control values 
(mean ± SO). NS = not signiticant. *p < 0.01. **p < 0.001. 
The statistical differences from control were determined on the 
basis of the percent change from the control values. Note the 
disparate behavior of Purkinje tibers and ventricular muscle (see 
text) in terms of the effects of flecainide on repolarization. 
concentrations of flecainide, premature responses could not 
be elicited until the membrane had repolarized to -75 mV; 
the Vlllax of such an action potential was 135 Vis. 
The mean data on the effects of fiecainide on the effective 
refractory period relative to those on the APDso and APD90 
in Purkinje fibers (n = 6) and in ventricular muscle (n = 
5) are summarized in Figure 2. In the case of Purkinje fibers, 
the effective refractory period initially shortened (at con-
centrations 0.1 to I fLg/ml) in parallel with the acceleration 
of repolarization; at 10 fLg/ml, the effective refractory period 
tended to "normalize" to control values. In contrast, in 
ventricular muscle the effective refractory period increased 
as a function of flecainide concentration; however, the over-
all magnitude of change was greater than that in the action 
potential duration. 
Frequency-dependent effects on the V max of the action 
potential. The pertinent data from studies in five Purkinje 
fibers are summarized in Figure 3. At each stimulus fre-
quency indicated (from I to 5 Hz), Vlllax was determined 5 
minutes after the change in frequency. After this duration 
of stimulation, a steady state change in Vlllax had been es-
tablished in all preparations. Before flecainide was given, 
Vlllax of these fibers was affected little over the entire range 
of frequencies used. At each increment in frequency, fle-
cainide had a significantly greater depressant effect on Vlllax ' 
The difference was evident not only when the data were 
analyzed by comparing individual values with the control 
values but also when the effect was tested on the basis of 
the slopes of the changes induced by different stimulus 
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frequencies at a given drug concentration. At a concentration 
of 10.0 fLg/ml, it was not possible to elicit a response at 
stimulus frequencies greater than 3 Hz. The frequency-
dependent reduction in Vlllax induced by flecainide was also 
found in canine ventricular muscle fibers. 
Effects of flecainide on automaticity in canine Pur-
kinje fibers. The effects of flecainide on enhanced auto-
maticity induced by isoproterenol were determined in three 
Purkinje tiber preparations (Fig. 4). Superfusion with iso-
proterenol, 2 x 10 (, M, induced regular spontaneous firing 
at a mean rate of 46 beats/min (Fig. 4A); in the same prep-
aration, a rapid burst of irregular firing at a mean rate of 
182 beats/min was sometimes also seen (Fig. 4B). Flecain-
ide (0.1, 1.0 and 5.0 fLg/ml) concentrations reduced the 
mean rate of firing to 39, 36 and 26 beats/min, respectively 
(Fig. 4C to E). The two higher concentrations also abolished 
the rapid bursts of irregular firing. 
Figure 3. Influence of stimulus frequency (abscissa) on the effect 
of flecainide on V""" of Purkinje tibers (ordinate). Open cir-
cles = control; closed circles = flecainide. 1.0 ILg/ml (all the 
changes are signiticant compared with control, p < 0.(5); closed 
triangles = tlecainide. 5.0 ILg/ml (all the changes are signiticant 
compared with control. p < 0.01); closed squares = flecainide. 
10.0 ILg/ml (all the changes are signiticant compared with control. 
p < 0.0 I). Five Purkinje fibers were used for each set of studies. 
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Figure 4. Effects of varying concentrations of tle-
cainide on the cycle length and phase 4 depolari-
zation of "automatic " discharge in canine Purkinjc 
fibers . A. Spontaneous regular di scharge induced 
by isoproterenol (2 x 1O - 6M). B, Rapid burst of 
irregular discharge induced by isoproterenol (2 x 
1O - 6M). C,D and E, Progressive changes induced 
by 0.1, 1.0 and 5.0 j.tg/ml of tlecainide . Note the 
prolongation of the cycle length of the induced 
rhythm. 
c 
Calcium-dependent changes and effects on slow re-
sponse action potentials. The influence of elevating ex-
tracellular calcium concentration (Ca2 +)" from 1.8 to 7.2 
mM in the presence of f1ecainide was studied in Purkinje 
fibers and ventricular muscle (n =: 3) (Fig. 5). Under control 
conditions, (CaB)" =: 1.8 mM. f1ecainide 5 /Lg/ml short-
ened APD50 and APD'J() in Purkinje tibers (Fig. 58) and it 
lengthened both variables in ventricular muscle tibers (Fig. 
SE) . When (Ca2 + )" was increased to 7.2 mM. the APD,o 
and APD<)o in Purkinje fibers were lengthened by 56 and 
18%, respectively, when compared with the values obtained 
under the influence of the same concentration of the drug 
at 1.8 mM (Fig. 5C). However, in ventricular muscle under 
the same experimental conditions, f1ecainide shortened the 
APD,o and APD,!o by 19 and 13%, respectively. when com-
pared with the values obtained for these variables at 1.8 
mM (Ca2 I)". 
Figure 6 shows a representative set of records illustrating 
Figure 5. Intluence of high extracellular calcium 
concentration (Cae I )" on the effects of tlecainide 
on action potentials of Purkinje (A,B and C) and 
ventricular muscle fibers (D,E and Fl. A. Control. 
1.8 mM (Ca2+)" . B. Flecainide. 5 .0 j.tg/ml at 1.8 
mM (Ca2 t )" . C , Flecainide , 5.0 j.tg/ml at 7.2 mM 
(Ca2+)". D, Control , 1.8 mM (Ca2+)". E, Flecain-
ide , 5 .0 j.tglml at 1.8 mM (Ca2 + l". F . Flecainide, 
5.0 j.tg/ml at 7 .2 mM (Cal + )". In both types of 
fibers, high (Ca2+)" tended to attenuate the effects 
of tlecainide on repolarization (see text) . 
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the effects of f1ecainide on slow channel-dependent poten-
tials induced by high extracellular potassium concentration 
(K t )., and isoproterenol. 2 x 10 Cl M. The characteristics 
of the slow channel potentials produced in this manner were 
not influenced by the addition of tetrodotoxin (0.2 /Lg/ml). 
Flecainide. I /Lg/ml. had no significant effects on the slow 
response (Fig. 6C): when the concentrations were increased 
to 10 /Lg/ml there was a decrease in the amplitude of the 
action potential and in the Villa, (Fig . 6D) but the action 
potential was not abolished. However, the action potential 
was abolished when verapamil (I X 10 5 M) was added 
to the superfusate (Fig . 6E) . 
Discussion 
Comparison of ftecainide actions with those of other 
fast channel inhibitors. The dominant effects of ftecainide 
in various isolated cardiac tissues studied here are consistent 
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with a potent inhibitory action on the fast sodium current 
as indicated by the decrease in Vlllax (14) and the shift of 
the membrane responsiveness curve in the hyperpolarizing 
direction. Thus, in this respect, the actions of flecainide 
resemble those of the broad category of compounds that 
appear to exert their salutary effects on arrhythmias pre-
dominantly by prolonging sodium-mediated time-dependent 
refractoriness in cardiac muscle (15-17). However, our 
studies, which confirm and extend the observations of pre-
vious investigators (10,18), have also indicated that fle-
cain ide has additional significant electrophysiologic prop-
erties. These effects and those on Purkinje fiber automaticity 
may be relevant to the observed potent antiarrhythmic ac-
tions of the drug in experimental animals (1-3) and human 
patients (6-9). As in the case of many other sodium channel 
inhibitors (15,19-22), flecainide shifted the membrane re-
sponsiveness curve in the direction of more negative po-
tentials, indicating a change in dependence on voltage of 
the inactivation of the sodium channels. The data of Bor-
chard and Boisten (10) suggest that flecainide delays re-
covery of sodium channels from an inactivated state. Our 
data, as do those of Borchard and Boisten (10), also em-
phasize the use-dependent nature of the inhibitory effect of 
flecainide on sodium channels demonstrated over a wide 
range of stimulus frequencies, This is a property common 
to antiarrhythmic compounds of the local anesthetic type 
(15,16), It suggests that the salutary effect of this class of 
drugs is likely to be more pronounced in arrhythmias with 
longer rather than shorter cycle lengths, although such a 
possibility has not been critically evaluated or verified in 
patients. 
Flecainide effect on voltage-dependent and time-
dependent refractoriness and repolarization. From the 
standpoint of the overall antiarrhythmic actions of flecain-
ide, the effect of the drug on myocardial refractoriness is 
perhaps of the greatest significance. However, the impor-
tance of the disparate effects of the drug on the effective 
lACC Vol. 5, No.2 
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Figure 6. Effects of flecainide and verapamil on 
the slow response action potentials of ventricular 
muscle fiber. A, Control action potential. B, Slow 
response action potential induced by 20 mM K + 
and isoproterenol (2 x 1O- 6M). C, Effect of fle-
cainide (1.0 ~g/ml) on slow response action poten-
tial. D, Effect of flecainide (10.0 ~g/ml) on slow 
response action potential. E, Effect of verapamil (I 
x 1O- 5M) on slow response action potential. The 
data show that at high concentrations, flecainide 
may exert a weak slow channel inhibitory effect. 
refractoriness of the Purkinje fibers and of ventricular mus-
cle is uncertain. The effective refractory period in Purkinje 
fibers was shortened significantly at all effective drug con-
centrations despite comparable decreases in Vlllax ; thus, it 
appeared that the decreases in the voltage-dependent effec-
tive refractory period caused by the marked abbreviation of 
the APDl)() exceeded the lengthening of the time-dependent 
sodium-mediated effective refractory period in this tissue. 
At a 10 jig/ml drug concentration, however, the two ap-
parently competing effects were "balanced" so that no sig-
nificant net effect on the effective refractory period was 
found. 
DUferential effects on Purkinje fibers and ventricular 
muscle. It is conceivable that a "balance" in the disparate 
changes induced by flecainide in ventricular muscle and 
Purkinje fiber repolarization may not always be achieved. 
This may lead to exaggerated heterogeneity in the recovery 
of excitability with a tendency for focal re-excitation. It is 
possible that this is the basis for the observed arrhythmo-
genicity of flecainide (11,12) and other so-called class I c 
compounds such as encainide and its metabolites, which 
also exert a similar differential electrophysiologic effect on 
Purkinje fibers and ventricular muscle (23). It is noteworthy 
that antiarrhythmic drugs such as phenytoin and lidocaine 
(24,25), which act primarily by inhibiting sodium channels, 
also accelerate repolarization in cardiac muscle. They may 
shorten the effective refractory period over certain drug 
concentrations, but they do this in Purkinje fibers as well 
as in ventricular muscle. It has been suggested that the 
shortening of the APD90 by lidocaine was due to an increase 
in time-dependent potassium conductance (26). Recently, 
however, voltage clamp studies (27,28) have shown that 
the shortening of the APD90 by lidocaine is caused by the 
suppression of tetrodotoxin sensitive steady state sodium 
current. The tetrodotoxin-sensitive steady state sodium cur-
rent apparently contributes more to the Purkinje fiber plateau 
than to that of the ventricular muscle fibers because tetro-
l
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dotoxin was found to abolish the difference that exists be-
tween the action potential duration (APD) between Purkinje 
fibers and ventricular fibers (29). Thus it is possible that, 
as in the case of lidocaine, flecainide exerts an inhibitory 
action on the tetrodotoxin-sensitive steady state sodium cur-
rent accounting for the observed shortening of the APD90 
and APDso in Purkinje fibers due to the drug. The shortening 
of the action potential duration is also partially antagonized 
by elevating (Ca2+)o and, at least in high concentrations, 
flecainide inhibits the slow channel; this suggests that slow 
channel inhibition may also contribute to the observed short-
ening of the action potential duration. This possibility is 
further supported by the observation that even in ventricular 
muscle lower concentrations (up to 10 ILg/ml) of flecainide 
lengthen the APD9(h but at higher concentrations (30 ILg/ml) 
APD90 shortens and is associated with a significant negative 
inotropic propensity (10). 
Clinical correlates of flecainide in vitro effects. The 
clinical electrophysiologic effects of flecainide recently 
reported (30,31 ) are consistent with our overall in vitro data, 
but such data should be correlated with the clinical findings 
with caution because the effects of the drug in our studies 
were evaluated in healthy myocardial tissues only. Never-
theless, it is of interest that these two other studies have 
shown that intravenous f1ecainide lengthened the QRS du-
ration, prolonged the HV interval and increased the effective 
refractory period in the atrial, ventricle and accessory tracts 
with a minimal lengthening of the QT, interval. Similar 
findings have been demonstrated from the recordings of the 
right ventricular monophasic action potentials in patients 
given f1ecainide intravenously (19). As in our in vitro stud-
ies, the magnitude of the increase in the action potential 
duration was small and did not influence the QTc interval 
of the surface electrocardiogram, suggesting that increases 
in the ventricular effective refractory period observed in the 
same study in human subjects were due to a time-dependent 
inhibition of the sodium channel. 
Clinical implications. The clinical implications of the 
data from this study indicating the cellular basis for the 
known potent antiarrhythmic action of f1ecainide in exper-
imental animals should be emphasized. The action is dom-
inated by a striking concentration-dependent inhibitory ac-
tion on the fast sodium inward current associated with a 
change in time and a voltage-dependent refractoriness as 
well as the tendency to reduce enhanced automaticity. Thus, 
the compound is likely to be effective in arrhythmias due 
to both automaticity and reentry. Furthermore, because the 
drug has a striking effect on Villa, in cardiac muscle, it is 
likely to have a correspondingly marked depressant action 
on conduction, suggesting that in the presence of conduction 
system disease, potentially serious effects on conduction 
might result after the use of the compound. In contrast to 
the actions of many other antiarrhythmic agents which are 
sodium channel inhibitors, f1ecainide, like encainide, exerts 
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a differential effect on repolarization in ventricular muscle 
and Purkinje fibers, an effect that is likely to aggravate 
heterogeneity of excitability and refractoriness on the heart 
and tends to worsen ventricular tachyarrhythmias in certain 
patients. 
We acknowledge the secretarial assistance of Isabel Rocha and Lawrence 
Kimble. Flecainide was made available by Dr. D. Kvam of 3M Company 
(Riker Laboratories). We also thank Dr. Andrew Soli for giving us canine 
hearts from his laboratory. 
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